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Purpose: Transrectal ultrasonography (TRUS) is a non-invasive modality widely used 
in urology on an outpatient basis to measure the volume and anatomical structure of 
the prostate. However, the prostate volume measured by TRUS often varies from test 
to test. The aim of this study was to determine the clinical significance of the different 
shapes of the prostate, as shown by TRUS before and after transurethral resection of 
the prostate (TURP).
Materials and Methods: We evaluated 103 patients who underwent TURP. TRUS was 
performed preoperatively, and the International Prostatic Symptom Score (IPSS) and 
quality of life (QoL) were assessed preoperatively and at 6 months postoperatively. 
Patients were classified into two groups: patients with a bilaterally enlarged transi-
tional zone were assigned to group A, and those with a protruding retrourethral zone 
were assigned to group B.
Results: There were no statistically significant differences between the two groups in 
preoperative variables. However, postoperative IPSS scores were lower in group A than 
group B (9.87±6.15 vs. 13.18±8.07, p=0.02). With regard to postoperative IPSS scores 
relative to preoperative IPSS scores, both groups showed a significant decrease, but 
group A experienced a significantly greater decrease than group B (13.43±7.47 vs. 
8.67±8.33, p=0.005).
Conclusions: Patients with a prostate protruding into the bladder have less of a decrease 
in their IPSS scores after TURP, compared to patients that do not have prostate pro-
trusion, meaning that patients with protrusion experience less symptomatic relief.
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INTRODUCTION
Transrectal ultrasonography (TRUS) is a relatively non- 
invasive method that is widely used in urology on an out-
patient basis to evaluate the volume, anatomical structure, 
and shape of the prostate. The mean prostate size increases 
as a population ages, and, since the average life expectancy 
has increased in recent years, so has the mean prostate size 
[1]. Many mathematical formulas have been used to de-
termine the volume of the prostate, but the formula for an 
ellipsoid (transverse diameter x anteroposterior diameter
x cephalocaudal diameter x π/6) is generally accepted as 
the most reliable and accurate method. However, using 
TRUS to take measurements is known to result in 10-12% 
variability in the calculated volume upon repeated tests 
[2]. It is also known that there is an error of approximately 
17-22% when volumes calculated using TRUS measure-
ments are compared with direct volume measurements 
taken before and after prostate resection by robot-assisted 
radical prostatectomy [3]. These direct measurement 
methods have less variation than methods utilizing TRUS, 
primarily due to user-dependent variation. Prostates can Korean J Urol 2010;51:483-487
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Parameters Group A  Group B p-value
Age (years) 67.62±6.64 68.51±5.52  0.49
PSA (ng/ml)   3.67±4.20   5.69±11.13  0.19
Preoperative IPSS 23.31±7.11 21.86±7.64  0.33
Preoperative
  voiding symptom
13.81±4.94 12.97±4.64  0.38
Preoperative
  storage symptom
  9.53±3.22   9.00±4.02  0.46
Preoperative
  Qmax (ml/sec)
  8.18±4.14   6.16±3.66  0.03
Prostate vol (cm
3) 42.02±18.88 61.66±22.13 ＜0.001
Transitional zone
  vol (cm
3)
18.81±12.94 31.79±16.03 ＜0.001
Operation time (min) 36.57±14.84 43.45±19.57  0.06
Resection vol (cm
3) 11.65±9.26 17.58±10.86    0.007
Resection vol/
  prostate vol ratio (%)
26.89±13.35 27.48±12.93  0.82
Postoperative IPSS   9.87±6.15 13.18±8.07  0.02
Postoperative
  voiding symptom
  9.87±4.06   6.00±5.1    0.057
Postoperative
  storage symptom
  5.68±3.09   7.18±3.87    0.033
Postoperative 
  Qmax (ml/sec)
13.65±8.24 12.04±7.81  0.36
Values are presented as Mean±SD. PSA: prostate-specific anti-
gen, IPSS: International Prostate Symptom Score, Qmax: max-
imal flow rate
TABLE 1. Preoperative and postoperative values of the two 
groups (Mean±SD)
also be classified according to the shape observed on TRUS 
[4].
　Transurethral resection of the prostate (TURP) is an ef-
fective therapy for the treatment of benign prostatic hyper-
plasia (BPH) [5]. There have been studies concerning fac-
tors that can predict post-TURP results, and these results 
are currently known to be primarily related to prostate vol-
ume, urodynamic study (UDS) results, and the Interna-
tional Prostate Symptom Score (IPSS) [6,7]. However, as 
mentioned previously, prostate volume measurements are 
quite variable.
　According to a recent study of the factors predicting blad-
der outlet obstruction (BOO), prostate-specific antigen 
(PSA) level, prostate volume, and intravesical prostate 
protrusion (IPP) are significantly associated with the oc-
currence of BOO, IPP being the most closely associated [8].
　However, there have been few studies regarding the 
changes in IPSS scores, voiding and storage symptoms, im-
provements in quality of life (QoL), and urinary flow rate 
(UFR) after TURP according to the shape of the prostate. 
The aim of this study was to determine whether pre-
operative prostate shape has any effects on outcomes after 
TURP.
MATERIALS AND METHODS
One hundred and three patients were selected from a pop-
ulation of 652 who underwent TURP for BPH performed 
by a single urologist at Wonju Christian Hospital from 
January 2001 to June 2008. Among these patients, those 
with a urologic tumor, neurogenic bladder (including de-
trusor overactivity), urinary tract infection (UTI), or blad-
der stones that may affect voiding were excluded. These 
103 patients were selected because they could be followed 
up on for 6 months postoperatively, and they underwent 
preoperative TRUS and pre- and post-TURP IPSS evalua-
tions. Prior to TRUS, patients underwent several types of 
evaluations, including UDS, PSA, and urine analysis (UA). 
According to the results of TRUS, group A (type I) was de-
fined as patients with bilateral transitional area enlarge-
ment, and group B (type II and III) was defined as those 
with retrourethral zone proliferation without bilateral 
transitional area enlargement and with bilateral transi-
tional area enlargement. Changes in pre- and post-
operative IPSS scores and UFR were compared and ana-
lyzed retrospectively.
　TRUS images were obtained and reviewed by a single 
operator. The size of the prostate was measured using the 
formula for an ellipsoid. UFR was calculated with Med-
tronic DUET
Ⓡ system (MED TRONIC). Maximal urinary 
flow of the two groups was compared, and the amount of 
resected prostate tissue was determined by weighing the 
prostate tissue postoperatively. Statistical analysis was 
performed with SPSS 12.0K for Windows. A paired sample 
t-test was used to evaluate the pre- and post-TURP varia-
bles in the patients, a Student's t-test was used to evaluate 
the two groups, and a p-value of less than 0.05 was set as 
the threshold for statistical significance.
RESULTS
The mean age of the 103 patients was 67.94 years, with a 
range of 54 to 83 years. Sixty-six (64.1%) of the patients be-
longed to group A, and 37 (35.9%) belonged to group B. 
There were no statistically significant differences in age, 
PSA level, preoperative IPSS score, or duration of surgery 
between the two groups (Table 1).
　The prostate volume of group B was significantly larger 
than that of group A (61.66±22.13 vs. 42.02±18.88 cm
3, p
＜0.001), and the weight of the gross specimen was heavier 
in group B as compared to group A (17.58±10.86 vs. 11.65± 
9.26 g, p=0.007). However, the ratio between the size and 
the resected volume of the prostate was not significantly 
different between group B and group A (26.89±13.35% vs. 
27.48±12.93%, respectively).
　Preoperative UFR was significantly different between 
group A and group B (8.18±4.14 vs. 6.16±3.66, p=0.03). 
However, postoperative UFR was not significantly differ-
ent between the two groups (13.65±8.24 vs. 12.04±7.81, 
p=0.36). Also, when each group was compared pre- and 
postoperatively, each group had a significant improvement 
in UFR.
　Preoperative IPSS scores were not significantly different Korean J Urol 2010;51:483-487
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FIG. 1. Comparison of the two groups’ preoperative and post-
operative International Prostate Symptom Score (IPSS).
Preoperation Postoperation p-value
Group A
  IPSS 23.32±7.11 9.87±6.15 ＜0.001
  Voiding symptom 13.81±4.94 4.22±4.06 ＜0.001
  Storage symptom 9.53±3.22 5.68±3.09 ＜0.001
  QoL 4.77±1.37 2.28±1.37 ＜0.001
Group B
  IPSS 21.86±7.64 13.18±8.07 ＜0.001
  Voiding symptom 12.97±4.64 5.00±5.15 ＜0.001
  Storage symptom   9.00±4.02 7.18±3.87 0.005
  QoL   4.83±1.06 2.62±1.44 ＜0.001
Values are presented as Mean±SD. IPSS: International Prostate
Symptom Score, QoL: quality of life
TABLE 2. Preoperative and postoperative values of IPSS scores
and QoL score of the two groups (Mean±SD)
between group A (23.31±7.11) and group B (21.86±7.64); 
however, group A (9.87±6.15) had significantly lower IPSS 
scores than group A (13.18±8.07) postoperatively (p=0.02) 
(Fig. 1). Both groups had statistically significant decreases 
in their postoperative IPSS scores relative to their pre-
operative scores, but the change in group A was sig-
nificantly greater than that in group B (13.43±7.47 vs. 
8.67±8.33, p=0.005). QoL improved significantly from the 
preoperative to postoperative states in both groups, and 
there was no difference in the degree of improvement be-
tween the two groups (Table 2).
DISCUSSION
Voiding difficulty is problematic in daily life and lowers the 
quality of life in people affected by it. BPH is a common 
cause of voiding difficulty, and, as the average male life ex-
pectancy continues to increase, the number of males suffer-
ing from voiding difficulty secondary to BPH will increase 
accordingly. As a male ages, his probability of developing 
lower urinary tract symptoms (LUTS), for which BPH is the 
most common cause, increases [9,10]. Currently, Euro-
pean Association of Urology BPH guidelines recommend 
evaluating IPSS, digital rectal examination, serum crea-
tinine, UA, voiding charts, and UFR to assess the disease 
initially and recommend surgery and finasteride as 
treatment. TRUS is suggested as the evaluation tool. Even 
though TRUS is an effective method for determining pros-
tate volume [11-14], measurements using this modality 
can vary depending on the operator [3]. A reported error 
rate as high as 10-20% is associated with the timing of the 
performance of the procedure [2]. However, the volume of 
the prostate gland or the level of BOO have no significant 
relationship with the QoL or voiding symptoms [15].
　Medical and surgical methods of treating prostatic dis-
ease are available, and TURP is currently the most effec-
tive treatment method [5]. About 29% of patients with BPH 
undergo some type of surgery [16]. However, approx-
imately 5-35% of BPH patients who undergo TURP have 
no improvement in their symptoms [17]. Approximately 
10% of these patients actually develop detrusor muscle 
overactivity despite undergoing TURP [18], and this de-
trusor overactivity persists in about 30-50% of these pa-
tients who subsequently undergo prostatectomy [18,19].
　Persistent overactive bladder (OAB) after TURP was fre-
quently observed in patients 80 years of age and older [20], 
and more cases were found to be related to storage symp-
toms than voiding symptoms after TURP [21]. Also, when 
detrusor instability is present preoperatively, patients 
have a high probability of having persistent voiding dys-
function after TURP [22]. Detrusor overactivity was ob-
served in 52% of patients with BOO. Even with medical 
therapy, this overactivity continues for a long period of 
time. However, when BOO is treated by TURP or prostatec-
tomy, the incidence of detrusor overactivity decreases 
greatly and re-develops less frequently for at least the first 
five years after the operation [18].
　TURP often alleviates most OAB symptoms. This relief 
likely occurs because TURP destroys both the entire ur-
othelium and submucosal tissue of both the prostatic ure-
thra and bladder neck region. Accordingly, this OAB symp-
toms can be attenuated by denervation of the associated af-
ferent neurons [23]. According to the data from the con-
servative management, laser therapy, transurethral re-
section of the prostate (CLasP) study, side-fire laser treat-
ment of BOO was as effective as TURP in reducing OAB 
symptoms, and although side-fire laser treatment is not as 
effective as TURP in reducing mechanical obstruction, it 
is probably as effective at destroying the prostatic and blad-
der neck urothelium and suburethral structures [24]. 
Therefore, it is likely that both laser therapy and TURP are 
effective for reducing OAB symptom because they de-
nervate the afferent neurons responsible for initiating in-
voluntary detrusor muscle contraction [23].
　Our findings demonstrate that voiding and storage 
symptoms and QoL are improved after TURP in both 
groups. Additionally, the storage and voiding symptoms of 
group A were significantly more improved than those of 
group B. Bladder outlet obstruction has been shown to be 
more frequently found in patients with IPP, as compared Korean J Urol 2010;51:483-487
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to those without, which was the case with group B, as com-
pared to group A [25]. Furthermore, it is known that blad-
der outlet obstruction leads to structural changes in the 
bladder, such as thickening of the bladder wall and de-
creased bladder compliance. Also established is that thick-
ening of the bladder wall increases the amount of ex-
tracellular collagen and causes nerve thickening, inducing 
storage symptoms by activating unmyelinated C nerve fi-
bers that are nonexistent in the normal bladder [26]. As re-
ported by Mitterberger et al, this phenomenon is attribut-
able to physical alteration of the bladder neck and ischemia 
of the bladder; however, more anatomical research in this 
area is necessary [27].
　BPH presents clinically as BOO, but morphologically, 
the prostate can take various shapes. Wasserman classi-
fied prostatic hyperplasia as having seven distinct types 
and compared the ultrasonographic appearance of each 
type with its pathological appearance [4]. In the case of 
BOO caused by prostatic hyperplasia, TURP significantly 
improved voiding symptoms and QoL; however, in our 
study, group A had significantly greater improvement than 
group B. This result suggests that careful preoperative 
evaluation should be undertaken to determine if IPP is 
present, and sufficient consideration should be given dur-
ing surgery when the prostate is found to be protruding into 
the bladder.
CONCLUSIONS
Transurethral resection of the prostate is an exemplary 
method for treating prostatic hyperplasia. Most patients 
experience improvement in their symptoms after surgery, 
but 20-30% of patients have persistent symptoms, for 
which medical treatment is often required. Most notably, 
patients with IPP experience a smaller decrease in their 
IPSS scores after the operation than patients without IPP, 
meaning that patients with IPP experience less sympto-
matic relief on average. This phenomenon is a factor that 
affects the outcomes after TURP and, therefore, should be 
considered when selecting patients for this operation.
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